PrLZ, prostate‐specific isoform 1 of TPD52, has been identified to exert a tumor‐promoting effect by activating the STAT3/BCL2 pathway,[35] inhibiting LKB1/AMPK,[36] transactivating the androgen receptor[37] and enhancing chaperone‐mediated autophagy.[17] However, our results indicated that TPD52 could inhibit tumor progression via ATF6 branch of UPR in bladder cancer. Here, STK11 is linked to neoplasm.